Ubrogepant does not induce latent sensitization in a preclinical model of medication overuse headache

BACKGROUND: Ubrogepant, a small-molecule calcitonin gene-related peptide receptor antagonist, was recently approved as an oral medication for the acute treatment of migraine. This study aimed to determine whether ubrogepant shows efficacy in a preclinical model of migraine-like pain and whether repe...

Descripción completa

Detalles Bibliográficos
Autores principales: Navratilova, Edita, Behravesh, Sasan, Oyarzo, Janice, Dodick, David W, Banerjee, Pradeep, Porreca, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7412872/
https://www.ncbi.nlm.nih.gov/pubmed/32615788
http://dx.doi.org/10.1177/0333102420938652

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7412872/
https://www.ncbi.nlm.nih.gov/pubmed/32615788
http://dx.doi.org/10.1177/0333102420938652

Ejemplares similares